Jefferies Group LLC reaffirmed their buy rating on shares of Abeona Therapeutics Inc. (NASDAQ:ABEO) in a research note issued to investors on Wednesday morning. Jefferies Group LLC currently has a $28.00 price target on the biopharmaceutical company’s stock. Jefferies Group also issued estimates for Abeona Therapeutics’ Q4 2017 earnings at ($0.12) EPS, FY2017 earnings at ($0.59) EPS, FY2018 earnings at ($0.71) EPS, FY2019 earnings at ($0.19) EPS, FY2020 earnings at $0.57 EPS and FY2021 earnings at $1.97 EPS.

ABEO has been the topic of several other reports. Zacks Investment Research lowered shares of Abeona Therapeutics from a hold rating to a sell rating in a report on Tuesday, August 22nd. HC Wainwright reiterated a buy rating and issued a $30.00 target price (up from $20.00) on shares of Abeona Therapeutics in a report on Monday, October 9th. Royal Bank Of Canada started coverage on shares of Abeona Therapeutics in a report on Thursday, September 14th. They issued an outperform rating and a $23.00 target price on the stock. Maxim Group set a $17.00 target price on shares of Abeona Therapeutics and gave the stock a buy rating in a report on Tuesday, August 29th. Finally, Cantor Fitzgerald reiterated a buy rating and issued a $21.00 target price on shares of Abeona Therapeutics in a report on Friday, October 6th. One investment analyst has rated the stock with a hold rating and ten have given a buy rating to the company. The stock presently has a consensus rating of Buy and an average price target of $26.10.

Abeona Therapeutics (NASDAQ:ABEO) remained flat at $$16.15 on Wednesday. The company’s stock had a trading volume of 501,000 shares, compared to its average volume of 623,707. Abeona Therapeutics has a 12-month low of $4.05 and a 12-month high of $22.75.

Abeona Therapeutics (NASDAQ:ABEO) last posted its earnings results on Wednesday, November 15th. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.18) by $0.05. The company had revenue of $0.22 million for the quarter, compared to analyst estimates of $0.22 million. Abeona Therapeutics had a negative net margin of 2,946.58% and a negative return on equity of 27.69%. equities research analysts expect that Abeona Therapeutics will post -0.66 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This story was originally published by Watch List News and is the sole property of of Watch List News. If you are reading this story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright & trademark law. The legal version of this story can be viewed at https://www.watchlistnews.com/abeona-therapeutics-inc-abeo-given-buy-rating-at-jefferies-group-llc/1721709.html.

Several hedge funds have recently modified their holdings of ABEO. State of Wisconsin Investment Board bought a new stake in shares of Abeona Therapeutics during the second quarter worth $122,000. Rhumbline Advisers bought a new stake in shares of Abeona Therapeutics during the second quarter worth $190,000. Bank of New York Mellon Corp increased its position in shares of Abeona Therapeutics by 125.8% during the first quarter. Bank of New York Mellon Corp now owns 41,929 shares of the biopharmaceutical company’s stock worth $210,000 after acquiring an additional 23,358 shares in the last quarter. Schwab Charles Investment Management Inc. bought a new stake in shares of Abeona Therapeutics during the second quarter worth $264,000. Finally, California State Teachers Retirement System bought a new stake in shares of Abeona Therapeutics during the second quarter worth $275,000. 36.34% of the stock is owned by institutional investors.

About Abeona Therapeutics

Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB).

Analyst Recommendations for Abeona Therapeutics (NASDAQ:ABEO)

Receive News & Ratings for Abeona Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.